An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Volasertib (Primary) ; Itraconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 08 Jun 2017 Planned End Date changed from 1 Mar 2017 to 30 Jun 2017.
- 22 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
- 21 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.